These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18327222)

  • 1. Investor malaise stalks UK, European biotech.
    Mitchell P
    Nat Biotechnol; 2008 Mar; 26(3):256-7. PubMed ID: 18327222
    [No Abstract]   [Full Text] [Related]  

  • 2. UK biotech smashes financing record.
    Nat Biotechnol; 2015 Sep; 33(9):889. PubMed ID: 26348941
    [No Abstract]   [Full Text] [Related]  

  • 3. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotech slumps in Q1.
    Lawrence S
    Nat Biotechnol; 2008 May; 26(5):486. PubMed ID: 18464769
    [No Abstract]   [Full Text] [Related]  

  • 5. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotech R&D goes further afield.
    Lawrence S
    Nat Biotechnol; 2006 Sep; 24(9):1052. PubMed ID: 16964201
    [No Abstract]   [Full Text] [Related]  

  • 7. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 8. A special biotech speculation.
    Jacobs T
    Nat Biotechnol; 2006 Jun; 24(6):622. PubMed ID: 16763586
    [No Abstract]   [Full Text] [Related]  

  • 9. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

  • 10. Public biotech 2010--the numbers.
    Huggett B; Hodgson J; Lähteenmäki R
    Nat Biotechnol; 2011 Jul; 29(7):585-91. PubMed ID: 21747381
    [No Abstract]   [Full Text] [Related]  

  • 11. Public companies get creative in raising finance.
    Hodgson J
    Nat Biotechnol; 2010 Apr; 28(4):301-2. PubMed ID: 20379161
    [No Abstract]   [Full Text] [Related]  

  • 12. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. This means war.
    Nat Biotechnol; 2008 Sep; 26(9):954. PubMed ID: 18779784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Job insecurity.
    Smaglik P
    Nature; 2002 Oct; 419(6910):3. PubMed ID: 12410262
    [No Abstract]   [Full Text] [Related]  

  • 15. Troubled UK biotech firm faces new probe.
    Masood E
    Nature; 1998 Apr; 392(6679):852. PubMed ID: 9582060
    [No Abstract]   [Full Text] [Related]  

  • 16. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotech drug market steadily expands.
    Lawrence S
    Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
    [No Abstract]   [Full Text] [Related]  

  • 18. BioXell: an Italian biotech success story?
    Sheridan C
    Nat Biotechnol; 2006 Sep; 24(9):1045-6. PubMed ID: 16964198
    [No Abstract]   [Full Text] [Related]  

  • 19. Divining the path to a successful European exit.
    Buch HK; Gustafsson AC; Drvota V; Sundberg CJ
    Nat Biotechnol; 2011 Mar; 29(3):205-7. PubMed ID: 21510008
    [No Abstract]   [Full Text] [Related]  

  • 20. Pension plans dally with biotech.
    Ransom J
    Nat Biotechnol; 2006 Jun; 24(6):600. PubMed ID: 16763575
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.